Global Migraine Market Value To Grow Modestly By 2023 Despite Promising New Drugs, Says Globaldata
3/12/2014 10:01:47 AM
LONDON, UK (GlobalData), 12 March 2014 - The global migraine treatment market value is expected to undergo a modest increase over the coming years, climbing from $2.5 billion in 2012 to $3.7 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 3.6%, according to a new report from research and consulting firm GlobalData.
The company’s latest report* states that out of the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan), the US dominated the migraine space in 2012 with a global share of 77%. It will maintain its market-leading position by 2023, with a higher share of 84%.
GlobalData attributes the anticipated market expansion to the introduction of novel acute migraine therapy classes, which will address the underserved population. Among the drugs that will be launched during the forecast period are Teva and NuPathe’s Zecuity, Allergan’s Levadex, OptiNose’s AVP-825 and SUDA’s SUD-001.
Alvina To, GlobalData’s Therapy Analyst, says: “Teva and NuPathe’s Zecuity, the first and only iontophoretic transdermal system for migraine, will prove popular among the population that requires or prefers an alternative route of administration over the existing formulations of acute treatments. We expect the therapy to achieve sales of approximately $180.5 million by 2023.”
CoLucid’s lamiditan and Merck’s MK-1602, the first-in-class drugs for the ditans and gepants, are also new classes of acute therapies due to be launched in the next decade.
The analyst says: “The entrance of these drugs is set to boost the overall market size during the forecast period. Both therapies have the potential to steal shares from the existing triptans and ergot alkaloids, in addition to reaching patients who are unresponsive to existing medications. We forecast that CoLucid’s lamiditan and Merck’s MK-1602 combined sales will reach nearly $1.3 billion by 2023.”
Aside from new market entries, Alvina To says that the preventive migraine segment is unlikely to see any change in the development of new therapies. However, Allergan’s Botox, the only preventive treatment currently available for chronic migraine, is expected to continue driving market growth and remain leader in terms of sales during the forecast period.
*PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023
This report provides annualized migraine therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2023. Key topics covered include market characterization, unmet needs, Research and Development, clinical trials assessment, late-stage clinical trial analysis and implications for the migraine therapeutics market.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at firstname.lastname@example.org.
Help employers find you! Check out all the jobs and post your resume
comments powered by